Benefits and risks of combination therapy for hepatitis B.
about
Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.Combination treatment in HBeAg-negative chronic hepatitis B.Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach.Comparable efficacy with entecavir monotherapy and tenofovir-entecavir combination in chronic hepatitis B patientsCombinations of Oseltamivir and T-705 Extend the Treatment Window for Highly Pathogenic Influenza A(H5N1) Virus Infection in MiceMeta-analysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus.Hepatitis B therapies and antiviral resistance detection and management.Prolonged Combination Therapy is More Effective than Monotherapy in Management of Chronic Hepatitis B Patients With Sustained Virological Response: An Experience From a 'Real-World' Clinical Setting.Management of HIV and hepatitis virus coinfection.Tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.Interferon-alpha plus adefovir combination therapy versus interferon-alpha monotherapy for chronic hepatitis B treatment: A meta-analysis.Chronic hepatitis B virus infection: epidemiology, prevention, and treatment in China.Therapeutic strategies for a functional cure of chronic hepatitis B virus infection.A functional polymorphism in ADAR1 gene affects HBsAg seroclearance both spontaneously and interferon induced.Potential Efficacy of Pegylated Interferon-α and a Nucleos(t)ide Analogue as Combination Therapy for HBeAg-Positive Chronic Hepatitis B.Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis.De novo hepatitis B virus infection from anti-HBc-positive donors in pediatric living donor liver transplantation.Dual drug load and release behavior on ion-exchange fiber: influencing factors and prediction method for precise control of the loading amount.Studies on the non-invasive anticancer remedy of the triple combination of epigallocatechin gallate, pulsed electric field, and ultrasound
P2860
Q33865784-D1A025E4-886F-49B0-959D-5058743A6736Q34391476-B270136B-9CB0-4C8A-9A4F-307E94663785Q35422530-A230F046-6906-4B58-94AB-0075BA712B61Q36140470-389F5676-32BA-448F-A640-207F05745C99Q36934209-97A3D8C3-4E09-4900-9996-7210A8E43B4AQ37393925-C892A552-08F2-432F-830A-92BAEC399661Q37636111-55761686-202D-434C-A22A-608F9C35DBC1Q37639565-438F0366-51DC-4085-8CAF-2A799BFDF73BQ37772508-10CA8B49-F3D3-4DE2-ABED-D45AF4CA8419Q37800919-C9D61401-9DA9-44CF-97AC-D75C798CFBD0Q38077311-87C0DD4C-312F-48A4-9F78-590DF180B3FDQ38210344-0B6668C3-B723-4CB7-86C5-3A95C539AA70Q38636988-62E3EF0E-FE9B-4D78-8256-41F8D41BBDE1Q39042138-5360A376-D23E-4D46-AB68-F4CBE4E9ECC1Q41570841-4B13C8B2-4D13-4B42-9BB7-1C3163B4C480Q42245098-8DA588C1-8740-4B69-9285-BD184D82BCC2Q45333184-2266C227-02CD-4540-98BA-1BC384BE0DF7Q51084638-0A032519-ED1C-4554-ABA1-E2188319F71FQ58799777-DAB49F64-0B22-44DA-A7DD-EAA9CB92C9AB
P2860
Benefits and risks of combination therapy for hepatitis B.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Benefits and risks of combination therapy for hepatitis B.
@en
Benefits and risks of combination therapy for hepatitis B.
@nl
type
label
Benefits and risks of combination therapy for hepatitis B.
@en
Benefits and risks of combination therapy for hepatitis B.
@nl
prefLabel
Benefits and risks of combination therapy for hepatitis B.
@en
Benefits and risks of combination therapy for hepatitis B.
@nl
P2860
P356
P1433
P1476
Benefits and risks of combination therapy for hepatitis B.
@en
P2093
Norah A Terrault
P2860
P304
P356
10.1002/HEP.22921
P407
P433
P577
2009-05-01T00:00:00Z